Lipson Considers Tolerability When Selecting Immunotherapy for Metastatic Melanoma
Source: Targeted Oncology, February 2024
During a Targeted Oncology™ Case-Based Roundtable™ event, Evan J. Lipson, MD, and participants discussed tolerability factors that could influence the choice of frontline immunotherapy regimen for a patient with metastatic melanoma.
PARTICIPANTS: Neeraj Mahajan, MD | Shyamal Bastola, MD | Tareq Al Baghdadi, MD | Elaine Beed, MD | Timothy Adamowicz, DO | Timothy Moore, MD | Michael Nemunaitis, MD | Samer Ballouz, MD | Baidehi Maiti, MD | Roopa Srikantiah-Saha, MD
EVENT REGION Michigan and Ohio